AMACR and prostate carcinoma: In addition to prostate cancer, AMACR positivity has been demonstrated in 90% cases of HGPIN suggesting that the possibility of HGPIN must be carefully excluded by morphology and the use of basal cell markers, before AMACR positivity is used to establish the diagnosis of adenocarcinoma.